Healthcare
Stem Cell Authority, Ltd.(SCAL)
Live Price
Offline$0.0002
+0.00% today
1Y Change
+0.00%
Window
Jun 23, 2025 → Jun 18, 2026
- Market Cap
- —
- Revenue Growth
- 0.0%
- EPS Growth
- 0.0%
- Dividend Yield
- 0.0%
Coverage: 253 bars · Jun 23, 2025 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Stem Cell Authority, Ltd. (SCAL) is a Healthcare stock with listed on OTC. The stock last traded around $0.00 and up 0.0% across the available one-year price window (Jun 23, 2025 → Jun 18, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of 0.0%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS 0.0%, free cash flow 0.0% with operating margin 0.0% and ROIC 5.3%. Stock Foundry combines SCAL price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
The setup is mixed rather than one-directional
Revenue is 0.0% and EPS is 0.0%, while operating margin sits near 0.0%.
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SCAL
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
SCAL Max Drawdown
-50.00%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for SCAL and SPY.
Company Overview
Stem Cell Authority, Ltd.
Other OTC
Stem Cell Authority, Ltd., a technology development company, focuses on the collection and cryogenic preservation of stem cells. It specializes in the collection and cryogenic preservation of the hematopoietic stem cells from the umbilical cord blood; and the Miracle Mesenchymal stem cells from the Wharton's jelly inside the umbilical cord of a newborn child. The company's technology enables birthing professionals with a stem cell preservation program to serve their maternity patients in the United States. Stem Cell Authority, Ltd. is based in Fairlawn, Ohio.
- Leadership
- Carlzo Bernard Cardwell
- IPO Date
- Mar 17, 2005
- Street Address
- 123 South Miller Road
- Mailing
- Fairlawn, OH, 44333
- Region
- Fairlawn, OH, US
- Reporting Currency
- USD
- Investor Line
- 330-835-0200
- Last Updated
- May 4, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- —
- EV/EBITDA
- —
- Price/Sales
- —
- Price/Book
- —
Growth
- Revenue
- 0.0%
- EPS
- 0.0%
- Free Cash Flow
- 0.0%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- 7.1%
- ROIC
- 5.3%
Balance Sheet
- Debt/Equity
- —
- Current Ratio
- 0.00
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.